Toggle light / dark theme

We must become a multi-planet species

Former astronaut Jeffrey Hoffman: For the long-term survival of our species, we have to become a multi-planet being.


With our rising planet’s population competing for space and resources, some people are convinced we need to look beyond Earth to help ensure humanity’s survival. As Elon Musk, the entrepreneur behind space tourism company SpaceX told Aeon’s Ross Andersen: “I think there is a strong argument for making life multi-planetary in order to safeguard the existence of humanity in the event that something catastrophic were to happen.”

Last month’s NASA and SpaceX successful launch of astronauts from US soil for the first time in almost a decade, has reignited discussion about space travel to Mars and beyond. Musk has been pushing Mars colonisation as extinction insurance for more than a decade now and he told Andersen that he would need a million people to form a sustainable, genetically diverse civilisation. Andersen reports:

‘Even at a million, you’re really assuming an incredible amount of productivity per person, because you would need to recreate the entire industrial base on Mars,’ he said. ‘You would need to mine and refine all of these different materials, in a much more difficult environment than Earth. There would be no trees growing. There would be no oxygen or nitrogen that are just there. No oil.’

I asked Musk how quickly a Mars colony could grow to a million people. ‘Excluding organic growth, if you could take 100 people at a time, you would need 10,000 trips to get to a million people,’ he said. ‘But you would also need a lot of cargo to support those people. In fact, your cargo to person ratio is going to be quite high. It would probably be 10 cargo trips for every human trip, so more like 100,000 trips. And we’re talking 100,000 trips of a giant spaceship.’

Pioneering research reveals certain human genes relate to gut bacteria

The role genetics and gut bacteria play in human health has long been a fruitful source of scientific enquiry, but new research marks a significant step forward in unraveling this complex relationship. Its findings could transform our understanding and treatment of all manner of common diseases, including obesity, irritable bowel syndrome, and Alzheimer’s disease.

The international study, led by the University of Bristol and published today in Nature Microbiology, found specific changes in DNA — the chains of molecules comprising our genetic make-up — affected both the existence and amount of particular bacteria in the gut.

Lead author Dr David Hughes, Senior Research Associate in Applied Genetic Epidemiology, said: “Our findings represent a significant breakthrough in understanding how genetic variation affects gut bacteria. Moreover, it marks major progress in our ability to know whether changes in our gut bacteria actually cause, or are a consequence of, human disease.”

Alzheimer’s: New gene may drive earliest brain changes

A newly discovered Alzheimer’s gene may drive the first appearance of amyloid plaques in the brain, according to a study led by researchers at Columbia University Irving Medical Center.

Some variants of the gene, RBFOX1, appear to increase the concentration of protein fragments that make up these plaques and may contribute to the breakdown of critical connections between neurons, another early sign of the disease.

The finding could lead to new therapies that prevent Alzheimer’s and better ways of identifying people with the greatest risk of developing the disease.

David Sinclair seeks £100m for anti-aging fight

One of the world’s greatest anti-aging scientists continues his groundbreaking efforts. In the photo next to Dr David Sinclair, there is a fella who kind of looks like my friend, Dr Yuancheng Ryan Lu. Is that you? (Dr Lu has confirmed that he is indeed the scientist on the right. Dr Sinclair is on the left.)

I can’t wait to see what they develop next!


Harvard scientist David Sinclair is one of Longevity’s big hitters. Just a year after raising $50M in Series B financing, his company Life Biosciences LLC is looking for $100M to progress its anti-aging research [1].

Longevity. Technology: Life Biosciences had an original Series B goal of $25M; it doubled it. As NAD continues to embed in the anti-aging supplement marketplace, the company is looking to expand, with a range of subsidiaries under its Longevity umbrella. Although the company isn’t spilling any secrets on its proposed clinical trials, we will be sure to keep a close eye on progress.

Life Biosciences, valued last year at approximately $500M, is built on Sinclair’s experience as co-Director of the Paul F Glenn Center for the Biology of Aging at Harvard Medical School, as a genetics professor at Harvard University and on previously-founded companies Arc Bio, Genocea and Ovascience.

3 thoughts on “Arrival of Gene-Edited Babies: What lies ahead?”

By Valentina Lagomarsino figures by Sean Wilson

Nearly four months ago, Chinese researcher He Jiankui announced that he had edited the genes of twin babies with CRISPR. CRISPR, also known as CRISPR/Cas9, can be thought of as “genetic scissors” that can be programmed to edit DNA in any cell. Last year, scientists used CRISPR to cure dogs of Duchenne muscular dystrophy. This was a huge step forward for gene therapies, as the potential of CRISPR to treat otherwise incurable diseases seemed possible. However, a global community of scientists believe it is premature to use CRISPR in human babies because of inadequate scientific review and a lack of international consensus regarding the ethics of when and how this technology should be used.

Early regulation of gene-editing technology.

CRISPR-engineered T cells in patients with refractory cancer

:oooooo.


CRISPR-Cas9 is a revolutionary gene-editing technology that offers the potential to treat diseases such as cancer, but the effects of CRISPR in patients are currently unknown. Stadtmauer et al. report a phase 1 clinical trial to assess the safety and feasibility of CRISPR-Cas9 gene editing in three patients with advanced cancer (see the Perspective by Hamilton and Doudna). They removed immune cells called T lymphocytes from patients and used CRISPR-Cas9 to disrupt three genes (TRAC, TRBC, and PDCD1) with the goal of improving antitumor immunity. A cancer-targeting transgene, NY-ESO-1, was also introduced to recognize tumors. The engineered cells were administered to patients and were well tolerated, with durable engraftment observed for the study duration. These encouraging observations pave the way for future trials to study CRISPR-engineered cancer immunotherapies.

Science, this issue p. eaba7365; see also p. 976.

Unique Modifications in Shark Immunity Genes Uncovered

A new genomics study of shark DNA, including from great white and great hammerhead sharks, reveals unique modifications in their immunity genes that may underlie the rapid wound healing and possibly higher resistance to cancers in these ocean predators. This research brings us a few steps closer to understanding, from a genetic sense, why sharks exhibit some characteristics that are highly desirable by humans.

The rate we acquire genetic mutations could help predict lifespan, fertility

Differences in the rate that genetic mutations accumulate in healthy young adults could help predict remaining lifespan in both sexes and the remaining years of fertility in women, according to University of Utah Health scientists. Their study, believed to be the first of its kind, found that young adults who acquired fewer mutations over time lived about five years longer than those who acquired them more rapidly.

The researchers say the discovery could eventually lead to the development of interventions to slow the .

“If the results from this small study are validated by other independent research, it would have tremendous implications,” says Lynn B. Jorde, Ph.D., chair of the Department of Human Genetics at U of U Health and a co-author of the study. “It would mean that we could possibly find ways to fix ourselves and live longer and better lives.”

/* */